Verona Pharma Share Discussion Threads

[fatgreek] 24/11/2015 14:46

Double digit rise on the table? All buys today....

[fatgreek] 24/11/2015 11:55

Something must be brewing as all of a sudden two days on the bounce loads of buys....Looking good :)

[bangbang1] 24/11/2015 11:42

Great to see share price climibing back up with not many sellers about. Let hope the BOD are working on a deal

[fatgreek] 24/11/2015 11:40

The climb north continues...Bye bye 2p hello 4p

[fatgreek] 24/11/2015 08:52

Another good start....lots more blue please..

[fatgreek] 23/11/2015 15:01

Lots of buys today.....looking good...

[fatgreek] 23/11/2015 11:28

Looking like a nice big blue day :)

[fatgreek] 20/11/2015 12:56

Sorry is this your BB?

[vasilis] 20/11/2015 12:49

Fatgreek

Actually, it's over two months old (9 September 2015) and is a take from para.4 onwards as reported here -

[bangbang1] 20/11/2015 12:26

vasilis going OTT

[fatgreek] 20/11/2015 10:57

Also tried to cut and paste previous hard man report and seemed to be encrypted.Ie. When pasted all wording changes to numbers and mumbo jumbo.

[fatgreek] 20/11/2015 10:54

It's about a month old.

[vasilis] 20/11/2015 08:49

Fatgreek,

Re your post 4770 - 'found this on the internet' - kindly add the appropriate internet link so that we can see the full article including when it was actually published. Otherwise some may suspect that you are selectively posting out-dated, un-sourced pieces for purposes other than anything to do with adding any useful information.

Nothing in that piece is new and the fact that Ken Newman was appointed last December and which Dr Karlsson refers to in the last paragraph of that post leads me to suspect that what you have posted is quite old -

[fatgreek] 19/11/2015 21:45

Found this on the internet.....

The clinical trial success of a new formulation of the company’s lead compound, RPL554, is behind much of the optimism. It is expected that RPL554 will be indicated for chronic obstructive pulmonary disease (COPD), cystic fibrosis and potentially other indications. It works by the dual inhibition of PDE3 and PDE4 enzymes, leading to a synergistic increase in activity in many cell types. “The new formulation is a suspension, where small particles are dissolved slowly and take a longer time to traverse through the lungs and into the bloodstream. It’s given better tolerability: in fact, the suspension formulation is so well-tolerated that we could actually dose up about 16 times higher,” said Dr Karlsson.

He explained that the company has three options in terms of how to proceed with RPL554. The first option is to develop it for patients with breakthrough symptoms of COPD and end up in hospital, where they would be treated with RPL554 as an add-on therapy, remaining on the drug as an outpatient. He estimates that sales in such a setting could be more than $500 million annually. Another potential avenue would be to pursue the belief that if it works in the sickest patients, it’s likely to also work in moderate to severe COPD on a daily basis to prevent patients from being hospitalized, which is a much bigger market. The third option is to develop the therapy as a dry powder inhaler, rather than a nebulizer, which Dr Karlsson acknowledges is a much bigger development plan and would require a partner.

On any plans to expand the company’s geographical footprint, Dr Karlsson said: “The Canadian unit as it used to be is much reduced, and instead we hired Ken Newman as chief medical officer, and he’s based in New York. I can tell you, that is a sign of a focus on market as the first and foremost market of our nebulized drug.”

[fatgreek] 19/11/2015 13:37

Level 2 looking good4 vs 1Another decent buy and we should move up again.

[bangbang1] 16/11/2015 12:50

Not sure why the drop.

[fatgreek] 16/11/2015 12:42

Anyone know why the drop? Tree shake? Buying opportunity?

[fatgreek] 12/11/2015 14:22

With another buy another tick up coming.

[fatgreek] 12/11/2015 12:33

Another buy and looks like we could tick up again...

[drradcliffe] 10/11/2015 22:31

I don't think it's quite 99%! :-) There are quite a few posts from timbo003 and Vasilis too. (All very useful.) I bought back in recently. I'm not sure I have timed it perfectly but I think the prospects for Verona look good.

[fatgreek] 09/11/2015 11:23

Tempted to add to the 200k I bought friday....

[fatgreek] 09/11/2015 00:03

Just posting this as i have noticed this company has had this happen which is an extremely positive sign... there have been many director buys over the months previous.....it's the best indicator that these guys running VRP know that their purchases will be worth alot more in time to come..... my own opinion is we will get bought out but read the snipet below...this has happened here (all very good and extremely positive)...http://www.stockopedia.com/content/cluster-buys-a-vital-signal-when-tracking-directors-dealings-78337/Hunting for cluster buys With evidence suggesting that buying is a far more important indicator than selling, it's clear that directors' dealings can be a hugely revealing guide for outsiders. But while there are strict market rules in place for reporting when directors have bought and sold shares in their own companies, profiting from this information isn't entirely straightforward. However, cluster buys involving several directors over recent months is not only one of the most intuitive indicators when it comes to these trades, but the evidence suggests it's also one of the most profitable

[fatgreek] 08/11/2015 23:48

Merger fever sweeps pharmaAs the M&A frenzy continues, small companies will be critical to the ecosystem, adds Jan-Anders Karlsson, chief executive of biotech Verona Pharma. 'With so many deals, much of the low-hanging fruit (the mid-sized biotech companies) is gone, which gives room for the next crop of companies to move forward that are high-risk but with potentially transformative technologies,' he says